Ecolab are Impact Ambassadors for People, Planet, Business and Health, to the Pharma Industry Awards. The Impact Ambassador programme highlights thought leadership from companies supporting the sector in Ireland. BusinessRiver, organisers of the awards, caught up with Ecolab to find out how they see the future for the Irish pharma sector both here in Ireland and on a global scale.
What is your vision for the pharma/biopharma sector?
We strive to be the chosen contamination control partner for the pharma and biopharma sectors and to continue to deliver innovative solutions that enable our customers to mitigate the risk from microbial contamination.
What are the big trends of the next five years?
Why an SSE Airtricity energy audit was a game changer for Aran Woollen Mills on its net-zero journey
Getting solid legal advice early in your company’s journey is invaluable
Water pollution has no one cause but many small steps and working together can bring great change
Empowering women in pharma: MSD Ireland’s commitment to supporting diverse leadership
Regulatory compliance including the recent Annex 1 updates, the focus on sustainable production and minimising the environmental footprint and the need to consistently deliver new treatments in a safe and timely manner will continue to be key trends for the years ahead. Another key emerging trend is the growth and investment in the field of advanced therapy medicinal products.
How is Ireland viewed internationally across the global sector?
Ireland has shown itself to be a great place to invest and this is recognised globally and reflected in Ireland being the third largest exporter of pharmaceutical products in the world. With a versatile, diverse, and talented workforce, we anticipate additional investment in the sector as the industry continues to grow.
How does Ireland feature as part of your global strategy?
Ireland is a driving force for both the pharma and biopharma industry. We continue to invest in Ireland and support the ongoing growth in the market.
What does Ecolab seek to achieve as a member of the Irish pharmachem community?
At Ecolab, we pride ourselves on our high quality, efficient products along with unrivalled expertise in the field of microbial contamination. As members, we aim to collaborate on important, lifesaving projects with key stakeholders in the industry, supporting them at the various stages from drug discovery to production.
What is your own ESG/sustainability strategy?
Ecolab has a strong focus on sustainability and each one of our divisions have sustainability goals. It is important to protect our planet and is one of the key areas of focus within the pharmaceutical industry. In this case, Ecolab advocates for water and energy optimisation, recyclable solutions in the pipeline, and more. Ecolab is committed to driving exponential operational and sustainability results with our customers and also in our own manufacturing operations. We have had great success with water and energy optimisation at many customer sites and recently established a virtual power purchase agreement that will support the construction and operation of a five-turbine wind farm on the west coast of Finland. Ecolab has a strong focus on sustainability and are fast becoming global sustainability leaders.
How does this strategy help you achieve industry objectives?
Our strategies are fully aligned with industry trends and goals. It’s crucial for us to be able to support the industry on their evolution journey as well as to set the future pipeline for innovation around market needs.
How do you see yourself as leaders the industry?
We support this fast-growing industry with our chemistries, validation services, technical expertise, digital tools and training, to help ensure the manufacture of high-quality medicines and ultimately patient safety.
The Pharma Industry Awards took place at the Dublin Royal Convention Centre on Thursday, 10 November 2022, and attracted more than 150 submissions from the world’s leading pharmaceutical companies.
For more information see www.pharmaawards.ie.